Frontiers in pharmacology · 2026
Comparison of conbercept and ranibizumab for the treatment of idiopathic choroidal neovascularization using optical coherence tomography angiography and multifocal electroretinography.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Zhai Gaixia, Zhu Lin, Su Yuanzhen, Wang Zuofen
Аннотация
OBJECTIVE: This study aimed to compare the efficacies of conbercept and ranibizumab for the treatment of idiopathic choroidal neovascularization (ICNV) using optical coherence tomography angiography (OCTA) and multifocal electroretinography (mfERG).
METHODS: Sixty patients with ICNV were retrospectively assessed and followed up in this retrospective comparative cohort study. Thirty patients were assigned to the conbercept group, and 30 patients were assigned to the ranibizumab group. Patients in both groups were treated with 1+ pro re nata. Best-corrected visual acuity (BCVA), macular central retinal thickness (CRT), and CNV blood flow area before treatment and at 1, 3, 6, and 12 months after treatment were obtained. The first positive peak (P1) amplitude density in ring 1 and intraocular pressure (IOP) were recorded at baseline and the last follow-up.
RESULTS: The follow-up duration was 12 months. BCVA (logMAR) improved at 1, 3, 6, and 12 months after the injection, and the CRT and CNV blood flow area significantly decreased in both groups relative to their values before treatment (p < 0.05). The P1 amplitude densities in ring 1 at baseline were 50.97 ± 8.05 nv/deg2 and 52.50 ± 9.71 nv/deg2 in the conbercept and ranibizumab groups, respectively (p = 0.5080). The change in the P1 amplitude density from baseline to the last follow-up visit was statistically significant (p < 0.05) in both groups. No significant changes were noted in the BCVA, IOP, CRT, CNV blood flow area, and P1 amplitude density after treatment from the baseline for the two groups. The number of injections was 2.00 ± 1.05 for the conbercept group and 2.67 ± 1.06 for the ranibizumab group (p = 0.0077). No serious ocular complications such as endophthalmitis and systemic adverse reactions such as myocardial infarction or cerebral infarction occurred in both groups.
CONCLUSION: Compared with intravitreal ranibizumab, intravitreal conbercept had a similar therapeutic effect in improving the structure and function on ICNV but with fewer injections.
METHODS: Sixty patients with ICNV were retrospectively assessed and followed up in this retrospective comparative cohort study. Thirty patients were assigned to the conbercept group, and 30 patients were assigned to the ranibizumab group. Patients in both groups were treated with 1+ pro re nata. Best-corrected visual acuity (BCVA), macular central retinal thickness (CRT), and CNV blood flow area before treatment and at 1, 3, 6, and 12 months after treatment were obtained. The first positive peak (P1) amplitude density in ring 1 and intraocular pressure (IOP) were recorded at baseline and the last follow-up.
RESULTS: The follow-up duration was 12 months. BCVA (logMAR) improved at 1, 3, 6, and 12 months after the injection, and the CRT and CNV blood flow area significantly decreased in both groups relative to their values before treatment (p < 0.05). The P1 amplitude densities in ring 1 at baseline were 50.97 ± 8.05 nv/deg2 and 52.50 ± 9.71 nv/deg2 in the conbercept and ranibizumab groups, respectively (p = 0.5080). The change in the P1 amplitude density from baseline to the last follow-up visit was statistically significant (p < 0.05) in both groups. No significant changes were noted in the BCVA, IOP, CRT, CNV blood flow area, and P1 amplitude density after treatment from the baseline for the two groups. The number of injections was 2.00 ± 1.05 for the conbercept group and 2.67 ± 1.06 for the ranibizumab group (p = 0.0077). No serious ocular complications such as endophthalmitis and systemic adverse reactions such as myocardial infarction or cerebral infarction occurred in both groups.
CONCLUSION: Compared with intravitreal ranibizumab, intravitreal conbercept had a similar therapeutic effect in improving the structure and function on ICNV but with fewer injections.